表紙
市場調查報告書

敗血症治療藥的全球市場

Sepsis Therapeutics

出版商 Global Industry Analysts, Inc. 商品編碼 210344
出版日期 內容資訊 英文 79 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
敗血症治療藥的全球市場 Sepsis Therapeutics
出版日期: 2019年01月01日內容資訊: 英文 79 Pages
簡介

本報告提供全球敗血症治療藥市場相關調查分析,提供美國及全球其他各國等市場別相關分析,再彙整今後的市場預測,主要企業簡介等相關資訊。

第1章 簡介,調查方法,產品定義

第2章 摘要整理

  • 產業概要
    • 敗血症治療藥的簡介
    • 敗血症專用治療藥的缺失
    • 開發中止或退出市場的敗血症治療藥候補
    • 競爭和開發平台
    • 用於目前敗血症第一療法之抗生素類別
    • 主要的管線藥:2016年
    • 現在與未來的分析
    • 促進成長要素
    • 市場抑制因素
    • 臨床試驗策略重新評估的必要性
    • 新免疫的作用機構受到關注
    • 藥物抗性的威脅
    • 老年人口統計
  • 敗血症治療藥的創新
  • 敗血症概要
  • 臨床試驗
  • 產品的引進與核准
  • 近來產業活動
  • 全球主要企業
    • Adrenomed AG (德國)
    • AM-Pharma B.V. (荷蘭)
    • Aridis Pharmaceuticals, Inc. (美國)
    • Asahi Kasei Pharma America (美國)
    • Astellas Pharma Inc. (日本)
    • Bristol-Myers Squibb Company (美國)
    • Chong Kun Dang BiO Corp. (韓國)
    • Endacea, Inc. (美國)
    • InflaRx GmbH (德國)
    • Opsona Therapeutics Ltd. (愛爾蘭)
    • Opsonix, Inc. (美國)
    • T2 Biosystems, Inc. (美國)
    • TaiRx, Inc. (美國)
    • TiGenix NV (比利時)
  • 全球市場概要

第3章 市場

  • 美國
  • 全球其他各國

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-6525

This report analyzes the worldwide markets for Sepsis Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2024. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 24 companies including many key and niche players such as -

Adrenomed AG
AM-Pharma B.V
AMOMED Pharma GmbH
Asahi Kasei Pharma America
Endacea, Inc.
InflaRx N.V.

Table of Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Data Interpretation & Reporting Level
  • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

2. INDUSTRY OVERVIEW

  • Sepsis - A Prelude
  • New Treatment Protocols and New Definitions - Every Minute Counts!!
  • Aging Population: A Key Growth Driver for Sepsis Therapeutics
    • Table 1: Global Population Statistics for the 60+ Age Group (2017E) (includes corresponding Graph/Chart)
    • Table 2: Global Population by Age Group: Percentage-wise Breakdown for Different Age Groups for Years 2017, 2050, and 2100 (includes corresponding Graph/Chart)
    • Table 3: Global Population Statistics for the 60+ Age Group by Region (2017)
    • Table 4: Life Expectancy for Select Countries in Number of Years: 2016 (includes corresponding Graph/Chart)
  • Antibiotics and Vasopressors - The Current Standard of Care
  • Current Categories of Antibacterial Agents for First-line Sepsis Treatment
  • Current Anti-bacterial Drugs used in Sepsis
  • Current Antifungals used for Sepsis
  • Current Antivirals used for Sepsis
  • GIAPREZA - The Only FDA Approved Branded Drug for Sepsis Treatment
  • Argipressin Gains Approval for Septic Shock in 26 EU countries
  • Current & Future Analysis
  • Growth Drivers in a Nutshell
  • Market Restraints

3. MARKET DYNAMICS

  • A Market Characterized by High Unmet Medical Needs
  • Research Activity Enables Increased Awareness of Disease Pathogenesis
  • Select Sepsis Therapeutics under Phase IV Clinical Trials: As of 2018
  • Select Sepsis Therapeutics under Phase III Clinical Trials: 2018
  • Novel Immune-Specific Modes of Action under Focus
  • Emphasizing on Endothelial Cell Function
  • HMGB1- A Potential Target for Future Therapies
  • Nanoparticle Systems Demonstrate Potential for Use in Septic Shock Management
  • Researchers Employ IL-7 to Increase CD4 and CD8 Immune Cells in Patients
  • Hydrocortisone Displays Potential in Septic Shock Treatment
  • Reduced Levels of Vitamin C Characterize Sepsis Patients
  • Treatment with Hydrocortisone and Vitamin C Demonstrates Positive Impact on Mortality Rate
  • Intravenous Vitamins + Hydrocortisone Therapy Causes Waves in the Market
  • Researchers Develop ss-Sepsis-3 Protocol for Evaluation of Sepsis in Animal Models
  • World Sepsis Day Aims to Result in Improvement in Sepsis Management
  • NSAIDs Demonstrate Potential to Treat Sepsis

4. SEPSIS: AN OVERVIEW

  • Sepsis - A Major Life-Threatening Condition
  • Risk Profile
  • Most Vulnerable Groups: Newborns and the Elderly
  • A Growing Threat in Hospital Environment
  • Types of Sepsis
  • SIRS
  • Uncomplicated Sepsis
  • Severe Sepsis
  • Septic Shock
  • Septicemia
  • Bacteremia
  • Mortality Rates
  • Mortality Rate on a Decline
  • Hospital Re-Admission Rate Remains High
  • Symptoms to Identify Sepsis Patients
  • General Symptoms in Sepsis Patients
  • Symptoms Specific to Source of Infection
  • Biological Changes in Sepsis Patients
  • Organ Dysfunction Symptoms in Acute Cases
  • Common Sources of Sepsis
  • Stages of Sepsis' Progression
  • Treatment of Sepsis
  • General Approaches for Treatment of Severe Sepsis and Septic Shock
  • Overview of Traditional Treatment Approaches
  • Anti-microbials
    • Drug Resistance: The Major Threat to Sepsis Standby Antibiotics
  • Vasopressors
  • Corticosteroids
  • Immunoglobulins
  • Anticoagulants
  • Neonatal Sepsis

5. COMPETITIVE LANDSCAPE

  • 5.1 Focus on Select Global Players
  • Adrenomed AG (Germany)
  • AM-Pharma B.V. (Netherlands)
  • AMOMED Pharma GmbH (Austria)
  • Asahi Kasei Pharma America (USA)
  • Endacea, Inc. (USA)
  • InflaRx N.V. (Germany)
  • La Jolla Pharmaceutical Company (USA)
  • TaiRx, Inc. (USA)
  • 5.2 Product Introductions/Approvals
  • Asahi Kasei Pharma Obtains Phase III Clinical Study Results for ART-123
  • Argipressin Receives Approval in 26 EU Countries
  • La Jolla Pharmaceutical Receives FDA Approval for Giapreza Injection
  • Sepsis Alliance Partners with La Jolla Pharmaceutical

6. GLOBAL MARKET PERSPECTIVE

    • Table 5: World Recent Past, Current & Future Analysis for Sepsis Therapeutics by Geographic Region/Country - US, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2018 through 2024 (includes corresponding Graph/Chart)
    • Table 6: World 5-Year Perspective for Sepsis Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, and Rest of World Markets for Years 2018, 2021, and 2024 (includes corresponding Graph/Chart)

7. REGIONAL MARKET PERSPECTIVE

  • 7.1 The United States
  • A. Market Analysis
    • United States: The Largest Market for Sepsis Therapeutics
    • Alarming Incidence of Sepsis & Lack of Therapies
    • Table 7: Estimated Annual Incidence of Septic Shock in the US (2016 - 2022E) (includes corresponding Graph/Chart)
    • Aging Population: A Key Growth Factor
    • Table 8: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
    • Table 9: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 10: The US Recent Past, Current & Future Analysis for Sepsis Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2018 through 2024 (includes corresponding Graph/Chart)
  • 7.2 Rest of World
  • A. Market Analysis
    • Aging Population: Key Opportunity Indicator
    • Table 11: Aging Population in Canada (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
    • Table 12: Aging Population in Europe by Country (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
    • India
      • India: High Incidence of Neonatal Sepsis
    • Table 13: Estimated Incidence and Mortality Associated with AIDS, Breast Cancer, MI, and Sepsis in India (includes corresponding Graph/Chart)
      • Key Opportunity Indicator: Aging Population Statistics in Rest of World
    • Table 14: Aging Population in Asia-Pacific by Country (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
    • Table 15: Aging Population in Latin America by Country (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
    • Table 16: Aging Population in the Middle East by Country (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
    • Table 17: Aging Population in Africa by Region (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 18: Rest of World Recent Past, Current & Future Analysis for Sepsis Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2018 through 2024 (includes corresponding Graph/Chart)

8. COMPANY PROFILES

  • Total Companies Profiled: 24 The United States (7) Canada (3) Japan (1) Europe (8) - France (1) - Germany (4) - Rest of Europe (3) Asia-Pacific (Excluding Japan) (4) Middle East (1) SEPSIS THERAPEUTICS MCP-6525 CONTENTS
Back to Top